Tidal Investments LLC Has $5.65 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Tidal Investments LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 75.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 20,544 shares of the biopharmaceutical company’s stock after acquiring an additional 8,811 shares during the period. Tidal Investments LLC’s holdings in Alnylam Pharmaceuticals were worth $5,650,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ALNY. Los Angeles Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares during the last quarter. Breakwater Capital Group bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $249,000. Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $578,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Alnylam Pharmaceuticals by 22.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after acquiring an additional 13,422 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $7,009,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $245.44 on Friday. The firm has a market capitalization of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a 50 day moving average price of $267.01 and a two-hundred day moving average price of $248.16. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the prior year, the business earned $1.15 EPS. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on ALNY. JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, TD Cowen boosted their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock worth $2,540,455 over the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.